Illumina, Roche Enter Partnership to Use Genomics for Medical Diagnosis
January 13 2020 - 1:14PM
Dow Jones News
By Stephen Nakrosis
Illumina Inc. (ILMN) Monday said it entered a non-exclusive
agreement with Roche to accelerate the use of genomics for medical
diagnosis.
Illumina and Roche announced a 15-year, non-exclusive agreement
to "broaden the adoption of distributable next-generation
sequencing-based testing in oncology."
Under the terms of the deal, Roche will receive rights to
develop and distribute in-vitro diagnostic tests using Illumina
technology, such as the NextSeq 550DX System. Illumina said Roche
will develop, manufacture and commercialize AVENIO IVD tests for
use on the NextSeq 550Dx System. Illumina will continue to sell the
system and core sequencing consumables, it said.
Roche will also work to complement Illumina's TruSight Oncology
500 pan-cancer assay, the companies said.
Financial terms of the deal weren't disclosed.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 13, 2020 12:59 ET (17:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
